Company News
- CTD Holdings Closes $2.00 Million Private Placement
Apr 23, 2018, 8:00 AM EDT - CTD Holdings Finalizes Cooperative Agreement for Alzheimer's Disease Research Program
Apr 19, 2018, 8:00 AM EDT - CTD Holdings Conducts Initial Review of Safety Data for its Phase I and Phase I/II Trials of Trappsol(R) Cyclo(TM) to Treat Niemann-Pick Disease Type C
Mar 29, 2018, 1:45 PM EDT - Randall M. Toig, M.D. Joins CTD Holdings Board of Directors
Mar 20, 2018, 8:00 AM EDT - CTD Holdings Announces FDA Authorization to Proceed with Single Patient IND for Use of Trappsol(R) Cyclo(TM) to Treat Alzheimer's Disease
Mar 12, 2018, 9:04 AM EDT - CTD Holdings Initiates Research Program to Explore Cyclodextrin Therapy for Alzheimer's Disease
Jan 29, 2018, 8:00 AM EST - CTD Holdings' European Clinical Trial Adopted by National Institute for Health Research of England
Jan 16, 2018, 8:00 AM EST - CTD Holdings Receives Rare Pediatric Disease Designation for Trappsol(R) Cyclo(TM)
Dec 6, 2017, 8:00 AM EST - CTD Holdings Closes $1.5 Million Private Placement
Oct 18, 2017, 8:00 AM EDT - CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C
Sep 28, 2017, 8:00 AM EDT
